MY170949A - A peptide capable of binding with a human leukocyte antigen (hla) molecule, a cancer vaccine derived from said peptide and use of said cancer vaccine - Google Patents

A peptide capable of binding with a human leukocyte antigen (hla) molecule, a cancer vaccine derived from said peptide and use of said cancer vaccine

Info

Publication number
MY170949A
MY170949A MYPI2011003259A MYPI2011003259A MY170949A MY 170949 A MY170949 A MY 170949A MY PI2011003259 A MYPI2011003259 A MY PI2011003259A MY PI2011003259 A MYPI2011003259 A MY PI2011003259A MY 170949 A MY170949 A MY 170949A
Authority
MY
Malaysia
Prior art keywords
peptide
cancer vaccine
hla
binding
molecule
Prior art date
Application number
MYPI2011003259A
Inventor
Sok Ching Cheong
Soo Hwang Teo
Kue Peng Lim
Mohd Zain Rosnah
Ariff Abdul Rahman Zainal
Ponniah Sathibalan
Original Assignee
Cancer Res Initiatives Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Res Initiatives Foundation filed Critical Cancer Res Initiatives Foundation
Priority to MYPI2011003259A priority Critical patent/MY170949A/en
Priority to PCT/MY2012/000198 priority patent/WO2013009165A1/en
Priority to TW101124710A priority patent/TWI567088B/en
Publication of MY170949A publication Critical patent/MY170949A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The present invention relates to a peptide comprising at least an amino acid sequence selected from at least a portion of MAGE-D4b protein, which the peptide is capable of binding with at least a human leukocyte antigen (HLA) molecule. The binding of the peptide with the human leukocyte antigen (HLA) molecule described herein, is capable of inducing the immune system of a subject to recognize oral cancer cells as being foreign. Upon being recognized as foreign particles, these cells are targeted and destroyed by the CD8+ cytotoxic T cells. Further disclosed in the present invention is a cancer vaccine derived from the MAGE-D4b peptides and the use of said cancer vaccine. Most illustrative drawing: Figure 1
MYPI2011003259A 2011-07-11 2011-07-11 A peptide capable of binding with a human leukocyte antigen (hla) molecule, a cancer vaccine derived from said peptide and use of said cancer vaccine MY170949A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
MYPI2011003259A MY170949A (en) 2011-07-11 2011-07-11 A peptide capable of binding with a human leukocyte antigen (hla) molecule, a cancer vaccine derived from said peptide and use of said cancer vaccine
PCT/MY2012/000198 WO2013009165A1 (en) 2011-07-11 2012-07-05 A peptide capable of binding with a human leukocyte antigen (hla) molecule, a cancer vaccine derived from said peptide and use of said cancer vaccine
TW101124710A TWI567088B (en) 2011-07-11 2012-07-10 Peptide capable of binding with a human leukocyte antigen (hla) molecule, cancer vaccine derived from said peptide, and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MYPI2011003259A MY170949A (en) 2011-07-11 2011-07-11 A peptide capable of binding with a human leukocyte antigen (hla) molecule, a cancer vaccine derived from said peptide and use of said cancer vaccine

Publications (1)

Publication Number Publication Date
MY170949A true MY170949A (en) 2019-09-20

Family

ID=47506273

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2011003259A MY170949A (en) 2011-07-11 2011-07-11 A peptide capable of binding with a human leukocyte antigen (hla) molecule, a cancer vaccine derived from said peptide and use of said cancer vaccine

Country Status (3)

Country Link
MY (1) MY170949A (en)
TW (1) TWI567088B (en)
WO (1) WO2013009165A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY192920A (en) 2017-03-15 2022-09-15 Cancer Res Malaysia Immunogenic peptide composition
KR102647696B1 (en) * 2017-06-05 2024-03-13 고쿠리츠다이가쿠호진 미에다이가쿠 Antigen-binding protein that recognizes peptides derived from MAGE-A4

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004026135A1 (en) * 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh Tumor-associated peptides binding to MHC molecules
SI1760089T1 (en) * 2005-09-05 2009-12-31 Immatics Biotechnologies Gmbh Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine
US20110236314A1 (en) * 2008-09-12 2011-09-29 Cancer Research Initiatives Foundation Method of detection and diagnosis of oral and nasopharyngeal cancers

Also Published As

Publication number Publication date
WO2013009165A1 (en) 2013-01-17
TW201302801A (en) 2013-01-16
TWI567088B (en) 2017-01-21

Similar Documents

Publication Publication Date Title
UA103751C2 (en) Immunogenic peptide for immunotherapy
NZ733168A (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
CY1123526T1 (en) INNOVATIVE IMMUNOTHERAPY AGAINST VARIOUS TUMORS INCLUDING NEURON AND BRAIN TUMORS
MX355074B (en) Diagnosis and treatment of cancer based on avl9.
BR112016009402A2 (en) PEPTIDE, ACTIVATED CYTOTOXIC T-LYMPHOCYTES (CTL), METHOD FOR THEIR PRODUCTION, ANTIBODY, T-CELL RECEPTOR, NUCLEIC ACID, HOST CELL, USE THEREOF, KIT, METHOD FOR PRODUCING A CUSTOMIZED ANTI-CANCER VACCINE FOR AN INDIVIDUAL PATIENT
MX2011011132A (en) Cancer antigen helper peptide.
MX2019005272A (en) Universal cancer peptides derived from telomerase.
EA201791925A1 (en) NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR THE APPLICATION IN IMMUNOTHERAPY OF SEVERAL TUMOR SPECIES
MX353165B (en) Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines.
WO2012069568A3 (en) Immunogenic peptides for use in the prevention and/or treatment of infectious diseases, autoimmune diseases, immune responses to allofactors, allergic diseases, tumors, graft rejection and immune responses against viral vectors used for gene therapy or gene vaccination
NZ712148A (en) Wt1 antigen peptide conjugate vaccine
MX2014004214A (en) Recombinant self-replicating polycistronic rna molecules.
DK2280721T3 (en) Indoleamin-2,3-dioxygenase-based immunotherapy
MX2016002937A (en) Oncology vaccine.
JP2014502961A5 (en)
NZ594198A (en) Neil3 peptides and vaccines including the same
NZ601980A (en) Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same
MX2012008657A (en) Modified melk peptides and vaccines containing the same.
MY170949A (en) A peptide capable of binding with a human leukocyte antigen (hla) molecule, a cancer vaccine derived from said peptide and use of said cancer vaccine
NZ611361A (en) Tomm34 peptides and vaccines including the same
MX2015009086A (en) Peptide.
MX2013004417A (en) Wdhd1 peptides and vaccines including the same.
SG10201408245WA (en) Tmem22 peptides and vaccines including the same
NZ746513A (en) Novel peptides and combination of peptides for use in immunotherapy against various tumors
MY182584A (en) Helicobacter pylori proteins for diagnostic kit and vaccine